KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Ionis Pharmaceuticals (IONS) over the last 17 years, with Q3 2025 value amounting to $2.4 billion.

  • Ionis Pharmaceuticals' Total Liabilities fell 14.5% to $2.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.4 billion, marking a year-over-year decrease of 14.5%. This contributed to the annual value of $2.4 billion for FY2024, which is 722.37% down from last year.
  • Latest data reveals that Ionis Pharmaceuticals reported Total Liabilities of $2.4 billion as of Q3 2025, which was down 14.5% from $2.4 billion recorded in Q2 2025.
  • Ionis Pharmaceuticals' 5-year Total Liabilities high stood at $2.6 billion for Q3 2023, and its period low was $1.6 billion during Q1 2021.
  • Moreover, its 5-year median value for Total Liabilities was $2.4 billion (2025), whereas its average is $2.2 billion.
  • In the last 5 years, Ionis Pharmaceuticals' Total Liabilities soared by 4327.52% in 2023 and then plummeted by 763.33% in 2024.
  • Over the past 5 years, Ionis Pharmaceuticals' Total Liabilities (Quarter) stood at $1.8 billion in 2021, then rose by 6.58% to $2.0 billion in 2022, then skyrocketed by 32.76% to $2.6 billion in 2023, then decreased by 7.22% to $2.4 billion in 2024, then fell by 0.01% to $2.4 billion in 2025.
  • Its Total Liabilities was $2.4 billion in Q3 2025, compared to $2.4 billion in Q2 2025 and $2.3 billion in Q1 2025.